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Research
Perinatal exposure to environmental chemicals, 
in particular those with estrogenic activity, can 
have long lasting consequences if exposure 
occurs during critical periods of reproduc-
tive tract development (Bern 1992; Marselos 
and Tomatis 1992a, 1992b; McLachlan and 
Newbold 1996; Newbold and McLachlan 
1996; Tomatis et al. 1992; Yamasaki et al. 
1992). More recent studies have further pro-
posed that hormonal perturbations during 
fetal or neo  natal development may predispose 
individuals to numerous diseases and/or dys-
function later in life, such as hypertension and 
coronary disease (Sallout and Walker 2003); 
obesity (Heindel 2003; Newbold et al. 2005, 
2007; Oken and Gillman 2003); reproduc-
tive problems including infertility/subfertility 
(Newbold 2004); and increased tumors such 
as uterine fibroids (leiomyomas) (Newbold 
et al. 2000) and breast cancer (Davis et al. 
1993). This phenome  non is referred to as “the 
develop  mental origins of health and disease” 
(Gluckman et al. 2005). The benign and 
carcinogenic effects of prenatal exposure to 
diethylstilbestrol (DES), a potent synthetic 
estrogen used to prevent miscarriage in the late 
1940s through the 1970s, is an example of the 
harmful effects that estrogenic chemicals can 
cause during development, many of which 
are not apparent until much later in adult 
life. Although the use of DES during preg-
nancy was discontinued > 30 years ago, we are 
still reminded of this chemical’s legacy as the 
DES-exposed offspring age and their health 
care problems continue to mount [National 
Institutes of Health (NIH) 1999; Palmlund 
1996] including the possibility of adverse 
effects on subsequent generations (Blatt et al. 
2003; Newbold 2004; Titus-Ernstoff et al. 
2008). Unfortunately, developing fetuses and 
young children continue to be inadvertently 
exposed to a wide number of environmental 
chemicals, many with hormone-like activity. 
Some of these chemicals occur in high pro-
duction volumes, and exposure comes from a 
number of different sources.
Bisphenol A (BPA), a monomer compo-
nent of polycarbonate plastics and epoxy res-
ins, is one such hormonally active chemical 
that is receiving increased attention due to 
its high production volume and widespread 
human exposure. BPA is used in the manu-
facture of numerous products and has been 
shown to leach from the linings of food cans 
(Brotons et al. 1994), polycarbonate baby 
bottles and other beverage containers (Biles 
et al. 1997), dental sealants and composites 
(Olea et al. 1996), and polyvinylchloride 
plastics and recycled thermal paper (European 
Communities 2008), suggesting that humans 
are routinely exposed to this chemical through 
numerous sources and routes of exposure. 
Further indication of human exposure is 
shown by studies reporting measurable BPA 
levels in human urine (Calafat et al. 2008), 
serum (Takeuchi and Tsutsumi 2002), breast 
milk (Ye et al. 2006), and maternal and fetal 
plasma, amniotic fluid, and placental tissues 
(Padmanabhan et al. 2008; Schonfelder et al. 
2002). 
BPA is most commonly described as 
being a “weak” estrogen; however, an emerg-
ing number of cellular and molecular stud-
ies show that it has potential for many other 
biological activities at environmentally rele-
vant exposures. In addition to binding to the 
nuclear estrogen receptors ER-α and ER-β, 
BPA interacts with a variety of other cellu-
lar targets including binding to a non  classical 
membrane-bound form of the ER (ncmER), 
a recently identified orphan nuclear receptor 
termed estrogen-related receptor-γ (ERRγ), a 
seven-trans  membrane estrogen receptor called 
GPR30, and the aryl hydrocarbon receptor 
(AhR). Interactions with ncmER and ERRγ 
are especially noteworthy because BPA binds 
to these receptors with high affinity. BPA also 
has been shown to act as an androgen recep-
tor antagonist and to interact with thyroid 
hormone receptors (for review, see Wetherill 
et al. 2007).
Studies in experimental animals have 
shown that very low doses of endocrine-dis-
rupting chemicals (Melnick et al. 2002), in 
particular BPA, in the range of human expo-
sures can exert effects if administered dur-
ing development (Markey et al. 2005). An 
increasing number of “low-dose” studies have 
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Ba c k g r o u n d: Exposure to endocrine-disrupting chemicals during critical developmental periods 
causes adverse consequences later in life; an example is prenatal exposure to the pharmaceutical 
diethylstilbestrol (DES). Bisphenol A (BPA), an environmental estrogen used in the synthesis of 
plastics, is of concern because its chemical structure resembles that of DES, and it is a “high-volume 
production” chemical with widespread human exposure. 
oBjectives: In this study we investigated whether prenatal BPA causes long-term adverse effects in 
female reproductive tissues in an experimental animal model previously shown useful in studying 
effects of prenatal DES. 
me t h o d s : Timed pregnant CD-1 mice were treated on days 9–16 of gestation with BPA (0.1, 1, 
10, 100, or 1,000 µg/kg/day). After delivery, pups were held for 18 months; reproductive tissues 
were then evaluated. 
re s u l t s: Ovarian cysts were significantly increased in the 1-µg/kg BPA group; ovarian cyst-
adenomas were seen in the other three BPA-treated groups but not in corn-oil controls. We 
observed increased progressive proliferative lesions of the oviduct after BPA treatment, similar to 
those described in response to DES. Further, although not statistically different from the controls, 
prominent mesonephric (Wolffian) remnants and squamous metaplasia of the uterus, as well as 
vaginal adenosis, were present in BPA-treated mice, similar to lesions reported following DES treat-
ment. More severe pathologies observed in some BPA-treated animals included atypical hyperplasia 
and stromal polyps of the uterus; sarcoma of the uterine cervix; and mammary adenocarcinoma. We 
did not observe these lesions in controls. 
co n c l u s i o n s: These data suggest that BPA causes long-term adverse reproductive and carcinogenic 
effects if exposure occurs during critical periods of differentiation.
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suggested that peri  natal BPA exposure is asso-
ciated a variety of abnormalities in the female 
reproductive tissues, including early onset of 
vaginal opening (Honma et al. 2002), early 
onset of puberty (Howdeshell et al. 1999; 
Ryan 2006), altered estrus cyclicity (Markey 
et al. 2003), altered plasma levels of luteiniz-
ing hormone (Rubin et al. 2001), altered vagi-
nal and uterine histology (Schonfelder et al. 
2002, 2004), alterations in the mammary 
gland (Markey et al. 2001) and uterus (Markey 
et al. 2005), and altered ovarian morphol-
ogy (Markey et al. 2003). Of greater concern, 
recent studies have reported an association 
of perinatal BPA exposure with more severe 
pathologies including preneoplastic and neo-
plastic lesions in male prostate (Ho et al. 2006) 
and female mammary gland (Durando et al. 
2007; Murray 2007). Although perinatal BPA 
exposure has been linked to early changes in 
the uterus, vagina, and ovary, no studies have 
examined the potential for low doses of BPA 
to cause potential carcinogenic alterations in 
these tissues. Low-dose exposure is particularly 
important because of its relevance to the levels 
experienced by the general human population 
(Calafat et al. 2008; Vandenberg et al. 2007).
The carcinogenic potential of BPA has been 
studied in vitro. High doses of BPA transform 
Syrian hamster embryo (SHE) cells and induce 
aneuploidy, suggesting that it has the potential 
to be geno  toxic (Tsutsui et al. 1998, 2000). 
At doses close to human exposure levels, BPA 
has not been previously shown to be a classical 
mutagen, although it does cause meiotic aneu-
ploidy in female germ cells grown in culture 
(Hunt et al. 2003). The National Toxicology 
Program (NTP) conducted in vivo carcino-
genic studies of BPA in which the chemical 
was adminis  tered to groups of mature male 
and female rats and mice; the study concluded 
that “there was no convincing evidence that 
BPA was a carcinogen” (NTP 1982). However, 
there was a lack of consensus for the NTP con-
clusion (Huff 2003) because cancers of the 
hematopoietic system, increases in interstitial 
cell tumors of the rat testis, and mammary 
gland fibroadenomas were reported in male 
rats (NTP 1982). Further, the full carcinogenic 
potential of BPA was not determined because 
the NTP study did not include developmental 
exposure (Huff 2003). 
The present study was designed to deter-
mine if prenatal exposure to BPA at low envi-
ronmentally relevant doses causes long-term 
adverse effects in reproductive tissues of aged 
females. Based on reported data (Markey et al. 
2005; vom Saal et al. 1997), we administered 
BPA to pregnant mice at 0.1–1,000 µg/kg 
maternal body weight on days 9–16 of ges-
tation, estimating that these doses are rele-
vant to human exposure (Calafat et al. 2008; 
Vandenberg et al. 2007). For example, esti-
mated daily intakes of BPA in formula-fed 
infants range from 1 to 13 µg/kg (NTP 2008). 
We chose to administer BPA by sub  cutaneous 
(sc) injection because this route has proven 
successful in duplicating and predicting the 
effects of oral DES exposure in humans 
(Newbold 2004). Additional support for using 
sc injections was shown recently by Taylor 
(2008) who found no effect of route of expo-
sure, either sc or oral, on plasma BPA levels in 
the neonatal female mouse. Also, in a study 
using adult mice, Alonso-Magdalena et al. 
(2006) showed that BPA treatment caused 
insulin resistance regardless of whether expo-
sure was by injection or oral treatment, sug-
gesting that the route of BPA exposure did not 
alleviate its effects. 
Materials and Methods
Animals and treatment. Adult female CD-1 
[Crl:CD-1 (ICR) BR] mice were obtained 
from Charles River Breeding Laboratories 
(Raleigh, NC) and bred to male mice of the 
same strain in the breeding facility at the 
National Institute of Environmental Health 
Sciences (NIEHS). Vaginal plug detection 
was considered day 0 of pregnancy. Pregnant 
mice were individually housed in polysulfone-
ventilated cages (Technoplast, Inc.; Exton, 
PA) with hardwood chip bedding under con-
trolled lighting (12 hr light/12 hr dark) and 
temperature (21–22°C) conditions. Mice were 
fed NIH 31 mouse chow, which was assayed 
for estrogenic activity as previously described 
(Thigpen et al. 1999), and fresh water was 
provided in polycarbonate water bottles 
ad libitum. All animal procedures complied 
with NIEHS/NIH animal care guidelines. 
All animals were treated humanely and with 
regard for alleviation of suffering.
Thirty timed pregnant mice (five per treat-
ment group) were injected sc with corn oil 
(control) or BPA (> 99% purity; Sigma-Aldrich, 
Table 1. Distribution of mice by treatment group.
Prenatal  No. of  No. of pups  Died early but not  Died early and   Total 
treatment  treated dams  at start  necropsied (n)a  necropsied (n)   no.
Control  5  16  0  0  16
BPA-0.1   5  16  2  1b  14
BPA-1   5  16  3  1c  13
BPA-10   5  16  2  1d  14
BPA-100   5  16  2  0  14
BPA-1000   5  16  3  3e  13
aNot included in the study. bAt 16 months of age. cAt 7 months of age. dAt 8 months of age. eTwo at 8 months of age and one 
at 10 months of age. 
Table 2. Incidence [fraction (%)] of abnormalities in the ovary/oviduct and uterus of aged mice treated 
pre  natally with BPA.
Prenatal treatment  Ovary/oviduct  Uterus
Control (n = 16)  No CL, 1/16 (6)   CEH, 2/16 (13) 
  Ovarian cysts, 4/16 (25)  Adenomyosis, 1/16 (6)
  PPL, 0/16 (0) 
BPA-0.1 (n = 14)  No CL, 2/14 (14)  CEH, 0/14 (0)
  Ovarian cysts, 4/14 (29)  Adenomyosis, 1/14 (7)
  PPL, 1/13a (8)  Atypical hyperplasia, 3/14 (21)
    Stromal polyp, 1/14 (7)
    Prominent Wolffian remnants, 1/14 (7)
BPA-1 (n = 13)  No CL, 3/12a (25)  CEH, 5/13 (38) 
  Ovarian cysts, 8/12a (67)*  Adenomatous hyperplasia, 1/13 (8)
  PPL, 1/12a (8)  Atypical hyperplasia, 2/13 (15)
    Squamous metaplasia, 1/13 (8)
    Stromal polyp, 1/13 (8) 
    Prominent Wolffian remnants, 1/13 (8)
BPA-10 (n = 14)  No CL, 1/14 (7)  CEH, 1/14 (7)
  Ovarian cysts, 2/14 (14)  Adenomyosis, 2/14 (14)
  Prominent paraovarian cysts, 1/14 (7)  Stromal polyp, 1/14 (7)
  Ovarian cystadenoma, 1/14 (7)  Prominent Wolffian remnants, 2/14 (14)
  PPL, 3/13a (23)
BPA-100 (n = 14)  No CL, 1/14 (7)  CEH, 5/14 (36)
  Ovarian cysts, 5/14 (36)  Squamous metaplasia, 2/14 (14)
  Ovarian cystadenoma, 1/14 (7)  Adenomatous hyperplasia, 2/14 (14)
  PPL, 3/13a (23)  Stromal sarcoma of cervix, 1/14 (7)
BPA-1000 (n = 13)  No CL, 1/13 (8)  CEH, 1/13 (8)
  Ovarian cysts, 5/13 (38)  Hyperplasia, 2/13 (15)
  Ovarian cystadenoma, 1/13 (8)  Hypoplastic, 1/13 (8)
  PPL, 2/13 (15)  Atypical hyperplasia, 1/13 (8)
    Prominent Wolffian remnants, 2/13 (15)
Abbreviations: CEH, cystic endometrial hyperplasia; CL, corpora lutea; PPL, progressive proliferative lesion of the oviduct. 
aAppropriate tissue sections of the ovary/oviduct were not available for one mouse in the treatment group. *p < 0.05 com-
pared with the control group, by Fisher’s exact test. Long-term effects of prenatal BPA
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Inc., St. Louis, MO) dissolved in corn oil on 
days 9 through 16 of gestation, the period of 
major organo  genesis in the murine reproduc-
tive tract. The daily dose of BPA was 0.1, 1, 
10, 100, or 1,000 µg/kg/day; we refer to the 
offspring of these animals as BPA-0.1, BPA-1, 
BPA-10, BPA-100, and BPA-1000, respec-
tively. Pregnant mice delivered their young on 
day 19 of gestation. We observed no significant 
difference in litter size between control and 
BPA-treated mice. To minimize any potential 
pre  natal litter effects, all pups in a treatment 
group were pooled together, separated by sex, 
and then fostered (four female and four male 
pups per litter) to moms of the same treatment 
group. Remaining male and female offspring 
were fostered to untreated moms and used in 
other experiments. At 21 days of age, offspring 
were weaned, separated by sex, housed four per 
cage, and held without further treatment. All 
mice were observed daily for sick and mori-
bund appearance. Table 1 summarizes the 
number and disposition of female offspring; 
results for males will be described in a separate 
report. 
Mice were euthanized by carbon diox-
ide asphyxiation at 16–18 months of age, or 
earlier if they were identified as being sick or 
moribund. Reproductive tract tissues includ-
ing ovaries and oviducts were removed, fixed 
in 10% neutral buffered formalin, embedded 
in paraffin, and sectioned at 6 µm. Tissue sec-
tions were stained with hematoxylin and eosin 
(H&E) and evaluated by light microscopy. 
A minimum of five serial sections of repro-
ductive tract tissues and nine ovary/oviduct 
sections were evaluated for each mouse. If a 
micro  scopic lesion was observed, additional 
serial sections were made to include the entire 
area of pathological change. In some cases, 
lesions were stained with Trichrome staining.
Statistical analysis. We used Cochran-
Armitage trend tests to evaluate dose-related 
changes in lesion incidence. We compared 
lesion incidence in each dose group with that 
in the control group using one-sided Fisher’s 
exact tests; p-values < 0.05 were considered 
statistically significant.
Results
Although we started with 16 mice per treat-
ment group, not all of the mice could be fol-
lowed until 16–18 months of age. However, 
84 of the 96 female mice were included. 
Table 1 shows the number of animals available 
at the end of the study and the frequency of 
sick and moribund animals. The BPA groups 
had more losses than the control group. 
Ovary/oviduct. A comparison of ovarian 
and oviductal abnormalities in control and 
BPA-treated mice is shown in Table 2. In mice 
16–18 months of age, we found no statisti-
cal difference in the number of mice without 
corpora lutea (CL) in any group. Cystic ovaries 
were also common in all groups, but only the 
BPA-1 group was significantly different from 
controls (p = 0.05). Prominent para  ovarian 
cysts of mesonephric origin were present in 
one BPA-10 mouse [7% (1/14)]. Further, 
neo  plastic lesions in the ovary included cyst-
adenomas (Figure 1A), which were present in 
the BPA-10, BPA-100, and BPA-1000 groups 
but not in controls. These lesions were lined 
by non  ciliated cubodial to columnar epithelial 
cells that were relatively uniform with basally 
located round nuclei.
We observed progressive proliferative 
lesion (PPL) of the oviduct in all groups of 
BPA-treated mice but not in controls. This 
oviductal abnormality has been previously 
described in prenatally DES-treated mice 
(Newbold et al. 1985). 
Uterus. The range of uterine abnormalities 
is also shown in Table 2. We observed cystic 
endometrial hyperplasia (CEH), a typical age-
related change in mice, in all groups (control, 
13%; BPA-1, 38%; BPA-10, 7%; BPA-100, 
36%; and BPA-1000, 8%) except the BPA-0.1 
group. Adenomyosis, characterized by benign 
invasion of endometrial glands into the myo-
metrium, occurred in the BPA-0.1, BPA-10, 
and control groups; adenomyosis has been 
reported to be prevalent in DES-treated mice 
(McLachlan et al. 1980; Newbold et al. 1990). 
Unlike DES-treated animals, the BPA-treated 
and control mice in the present study had a 
well-developed uterine muscle wall; thus 
this lesion was different from DES-induced 
changes. Because of this difference and because 
the lesion was also present in controls, we 
did not consider it to be treatment related. 
However, adenomatous hyperplasia with CEH 
Figure 1. Photomicrographs of representative examples of abnormalities (H&E-stained tissue sections) in mice prenatally treated with BPA. (A) Cystadenoma of the 
ovary (BPA-100) composed of anastomosing papillary fronds (arrow). (B) Adenomatous hyperplasia and CEH (arrow) in the uterus (BPA-1), characterized by hyper-
plastic endometrial glands and foci of cystic dilated glands lined by flattened epithelium; some secretory material is present in the lumen of some glands. (C) Higher 
magnification of (B) showing hyperplastic endometrial glands lined by cells with regularly shaped nuclei with little to no cellular pleomorphism or mitotic activity. 
(D) Atypical hyperplasia in the uterus (BPA-0.1) composed of foci of irregularly shaped glands with little intervening stroma (arrows). (E) Higher magnification of (D) 
shows “piling up” of cells (arrows) with hyperchromatic nuclei and many mitotic figures. (F) Endometrial polyps (P) extending into the uterine lumen (BPA-1). 
A B C
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was seen in the BPA-1 and BPA-100 groups 
(Figure 1B, C) but not controls. Further, the 
more severe lesion of atypical hyperplasia of 
the uterus (Figure 1D, E), which is considered 
a precursor lesion to estrogen-associated uter-
ine adenocarcinoma, occurred in 21% of the 
BPA-0.1, 15% of BPA-1, and 8% BPA-1000 
animals, but not in any controls in the present 
study or in historical controls. We observed 
prominent Wolffian (mesonephric) rem-
nants in the uterus similar to those seen in the 
ovary and oviduct in all BPA groups except 
BPA-100. Squamous metaplasia was also pres-
ent in the BPA-1 and 100 groups. 
Other lesions in the uterus included 
endometrial polyps, which were seen in the 
BPA-0.1, BPA-1 (Figure 1F), and BPA-10 
groups. These polyps were pedunculated 
masses with well-organized stromal and 
smooth muscle components. Figure 2A shows 
a large stromal polyp (BPA-10), which extends 
into the uterine lumen and has areas of CEH 
with secretory material; these stromal lesions 
have been reported to be associated with 
the development of stromal cell sarcomas in 
rodents (Davis et al. 1999; Maronpot 1999). 
In fact, one BPA-100 mouse had a stromal 
sarcoma that had infiltrated into the uterine 
cervix (Figure 2B).
Although sections through the vagi-
nal fornix were not always available, one 
BPA-1000 mouse had vaginal adenosis 
(Figure 2C, D) characterized by the abnormal 
location of “glandular structures” in the vagina. 
These glandular structures were lined by simple 
cuboidal to columnar epithelium. In one area, 
these cells had been replaced by squamous 
epithelium, and keratinizing cells were present 
in the glandular lumen (Figure 2C, D). Some 
of the glandular structures were connected 
to the vaginal lumen. Adenosis was reported 
in mice after pre  natal or neo  natal DES treat-
ment (Newbold and McLachlan 1982), and it 
was the hallmark lesion seen in DES-exposed 
women (Herbst 1981). 
In addition to mice that were sacrificed 
at the termination of the study, several mice 
became sick or moribund and were sacri-
ficed early. One BPA-1 mouse, sacrificed at 
7 months of age, had a poorly differentiated 
sarcoma that had invaded most of the repro-
ductive tract, ovaries, and all major organs; 
this lesion was probably hematopoetic in 
origin and not primary to the reproductive 
tract. A BPA-1000 mouse was sacrificed at 
10 months of age because of a large mam-
mary mass, which was diagnosed as adenocar-
cinoma (Figure 2E, F). Another similar tumor 
was found in a BPA-1 mouse at necropsy at 
18 months of age. We did not routinely screen 
the mammary gland, but these tumors were 
identified on gross examination at necropsy. 
The total number of mice with lesions 
shown in Table 3 suggests that, overall, BPA 
is associated with increased tumor incidence 
of reproductive tissues if exposure occurs 
during prenatal life. The lowest dose tested, 
BPA-0.1, demonstrates the highest tumor 
incidence (36% of mice).
Discussion
This article is the first to describe the induc-
tion of numerous abnormalities, including 
both benign and malignant lesions, in repro-
ductive tissues of aged female mice exposed 
prenatally to a broad range of BPA doses 
(0.1–1,000 µg/kg maternal body weight). 
The profile of reproductive tract lesions 
observed in this study is similar to what we 
observed following neonatal treatment with 
BPA (Newbold et al. 2007). The BPA doses 
were low and within the range of human 
exposure, comparable with 1–13 µg/kg esti-
mated intake levels of formula-fed infants and 
0.043–14.7 µg/kg in young children (NTP 
2008); further, these doses have been reported 
to cause pre  neoplastic and neo  plastic changes 
in peri  natally exposed male (Ho et al. 2006) 
and female (Durando et al. 2007; Murray 
2007; Newbold et al. 2007) experimental ani-
mal models. The present study adds to the 
growing body of literature that reports adverse 
effects following develop  mental exposure to 
low doses of BPA. 
Among the benign abnormalities was an 
elevated incidence of ovarian cysts (67% in the 
BPA-1 group). Although ovarian cysts are his-
tologically similar to those seen in our aged 
Figure 2. Photomicrographs of abnormalities in H&E-stained tissue sections from mice prenatally treated 
with BPA. (A) Endometrial stromal polyp (P) extending into the uterine lumen (BPA-10); note areas of CEH 
(arrow) with secretory material in glands. (B) Endometrial stromal sarcoma that has infiltrated into the 
uterine cervix (BPA-100). The lesion is composed of cells with pleomorphic nuclei with a moderate amount 
of mitotic activity; foci of inflammatory cells are indicated by the arrow. (C) Vaginal adenosis in tissue 
(BPA-1000) shows foci of “glandular structures” (G) lined by simple cuboidal to columnar epithelium. In 
one area, these “glands” were lined by squamous epithelium with keratinizing cells in the lumen (arrow); 
some of these glandular structures connected with the vaginal lumen (L), which is lined by stratified 
squamous epithelium. (D) Higher magnification of of vaginal adenosis in (C) showing glandular struc-
tures that connect to the squamous epithelium lining the vaginal lumen. (E) Mammary adenocarcinoma 
(BPA-1000) is a large solid tumor that has invaded the entire mammary structure and underlying muscle. 
(F) Higher magnification of (E) showing mammary adenocarcinoma composed of irregular shaped glands 
and pleomorphic cells with hyperchromatic nuclei. 
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controls, the incidence is significantly higher 
than the controls in this study (25%) and in our 
historical controls; interestingly, the incidence 
is similar to that reported following neonatal 
BPA exposure (70%) (Newbold et al. 2007). 
The incidence following either pre  natal or neo-
natal BPA is higher than we have observed in 
mice developmentally exposed to 0.001 mg/
kg DES (58%) (Newbold et al. 1990), 50 mg/
kg genistein (41%) (Newbold et al. 2001), or 
tamoxifen (60%) (Newbold et al. 1997), sug-
gesting that the ovary may be a particularly 
sensitive target for the effects of BPA. Ongoing 
studies in our laboratory are investigating this 
possibility as well as mechanisms involved in 
the formation of ovarian cysts.
In one BPA-10 mouse, we observed 
prominent paraovarian cysts of meso-
nephric (Wolffian) duct origin similar to 
those reported in neonatally exposed mice 
(Newbold et al. 2007). This lesion, combined 
with the finding of prominent cystic Wolffian 
duct remnants in the uterine wall of BPA 
mice, also suggests that the mesonephric duct 
system (Wolffian duct) may be a target of 
BPA because both cystic structures have the 
same fetal tissue origin. Mesonephric-derived 
tissues have been shown to be sensitive to 
the effects of perinatal DES exposure in both 
male (Newbold et al. 1985a) and female mice 
(Haney et al. 1986).
Another BPA-induced abnormality found 
in all dose groups is PPL of the oviduct. PPL 
has been described in mice perinatally treated 
with DES. DES was shown to interfere with 
the normal differentiation of the Mullerian duct 
(the precursor of the oviduct), resulting in struc-
tural (prenatal exposure) (Newbold et al. 1983) 
and cellular (neonatal exposure) altera  tions 
(Newbold et al. 1984, 1985b). The molecular 
mechanism likely involves altered HOX gene 
expression in the differentiation of the reproduc-
tive tract (Taylor et al. 1997) because prenatal 
DES delays the expression of these genes (Ma 
et al. 1998). Subsequent studies suggest that 
DES works through multiple gene pathways 
(Miller et al. 1998; Pavlova et al. 1994). Thus, 
molecular “mis  programming” is mostly likely 
responsible for DES, as well as BPA-induced, 
oviductal alterations. Whether these compounds 
cause these effects through the classical ER-α or 
ER-β, or the newly identified ncmER (Alonso-
Magdalena et al. 2005) pathways, or some other 
pathway, remains to be determined. 
The benign lesions (CEH and adenomyo-
sis) also occurred in the uterus of mice pre-
natally treated with BPA, but the incidence 
was not statistically different from controls. 
Although these lesions were histologically 
similar to those in aged controls, the lesions 
were more severe and their involvement in the 
uterine horns was more extensive in the BPA-
treated groups compared with controls in this 
study and with our historical controls. 
Of particular significance in this study is 
the occurrence of more severe ovarian lesions 
(cystadenoma) in the three highest BPA dose 
groups. In the uterus, adenocarcinoma was not 
observed in this study, although atypical hyper-
plasia, its premalignant lesion, was present. 
We were not suprised by the lack of uterine 
adenocarcinoma because BPA has weak ER-α 
binding and because the induction of uterine 
epithelial tumors is associated with a chemi-
cal’s binding affinity for this particular recep-
tor during neo  natal life (Newbold and Liehr 
2000; Newbold et al. 2006). In the uterus, we 
also found an increased incidence of stromal 
polyps in the BPA-100 group. These lesions are 
considered preneoplastic/neoplastic in experi-
mental rodent models because they are often 
the site for the development of endometrial 
stromal sarcoma (Davis et al. 1999; Maronpot 
1999). Historically, we have rarely seen stromal 
polyps in CD-1 mice, although we did observe 
this lesion in one control mouse in a previous 
study (Newbold et al. 2007). Interestingly, in 
the present study, we identified a large inva-
sive stromal sarcoma of the cervix after pre-
natal BPA-100 exposure; we have never seen 
this malignant lesion in any of our historical 
controls. Taking the stromal polyps and the 
stromal sarcoma together, these lesions sug-
gest that stromal tissue is a target for BPA 
exposure, especially if exposure occurs during 
critical periods of differentiation of the repro-
ductive tract. A similar finding has been shown 
in mice exposed to low-dose DES (Newbold 
et al. 2002). 
We identified adverse effects in the repro-
ductive tract in all BPA-treated groups, but it 
is interesting that the lowest dose (BPA-0.1) 
was the most affected (Table 3). Non  linear 
dose–response curves have been commonly 
reported in endocrinology studies (vom Saal 
et al. 1997). One explanation for these effects 
can be found in DNA micro  array studies 
(Coser et al. 2003; Shioda et al. 2006), where 
increasing doses of estrogens, from low to 
higher levels, result in entirely different arrays 
of genes that are turned on or off. Thus, the 
idea that there should be only a quantitative 
change in end points as the dose increases 
is not supported by these studies; instead, 
entirely different types of effects could occur 
as the high dose range is reached (for example, 
the changes we observed in the BPA-1000 
group in the present study). This requires 
further investigation; however, the pattern 
of non  monotonic effects is similar to what 
we observed in our neo  natal BPA study 
(Newbold et al. 2007).
In a previous NTP carcinogenesis bioas-
say, the NTP (1982) reported that adult expo-
sure to BPA was associated with cancers of the 
hematopoietic system. In the present study, 
we found one BPA-exposed mouse (BPA-1; 
7 months of age) had a poorly differentiated 
sarcoma that infiltrated one ovary and the entire 
reproductive tract; we consider this lesion to be 
hematopoietic in origin. Although this study 
was designed to address only long-term, mainly 
carcinogenic, effects of BPA on reproductive tis-
sues, certainly, the effects on the hematopoietic 
system warrants further follow-up. 
In the present study, body weights were 
not different between BPA-treated mice and 
control mice. This lack of difference is most 
likely due to the advanced age of the mice 
in the study. Our laboratory and others have 
previously reported that developmental expo-
sure to BPA, DES, and other environmental 
chemicals with endocrine-disrupting effects is 
associated with obesity in mice after they reach 
puberty and throughout maturity (Grun and 
Blumberg 2006; Grun et al. 2006; Howdeshell 
et al. 1999; Miyawaki et al. 2007; Newbold 
et al. 2005, 2007; Rubin et al. 2001); how-
ever, the animals in those studies were not 
examined at 18 months of age. Also, we have 
shown that significant differences in body 
weight in DES-treated mice compared with 
controls at 6–8 months of age become more 
difficult to detect as the animals age because 
of increased individual variability among all 
mice and because of increased disease and 
tumors (Newbold et al. 2007); thus, this vari-
ability probably accounts for lack of detection 
of body weight differences in this study. More 
important, we found no apparent correla-
tion of body weight and tumor occurrence in 
either individual animals or groups, although a 
few BPA-exposed mice (but no controls) died 
before the completion of the study. 
Table 3. Summary of preneoplastic and neoplastic lesions [fraction (%)] in the ovary/oviduct and reproduc-
tive tract of aged mice treated prenatally with BPA.
  Ovary/oviduct  Reproductive tract  Total no. with lesions
Prenatal  Incidence    Incidence    Incidence
treatment  of lesions  p-Valuea  of lesions  p-Valuea  of lesions  p-Valuea
Control (n = 16)  0/16 (0)  —  0/16 (0)  —  0/16 (0)  —
BPA-0.1 (n = 14)  0/14 (0)  —  4/14 (29)  0.04  5/14 (36)b  0.01
BPA-1 (n = 13)  0/13 (0)  —  3/13 (23)  0.08  4/13 (31)c  0.03
BPA-10 (n = 14)  1/14 (7)  0.47  1/14 (7)  0.47  2/14 (14)  0.21
BPA-100 (n = 14)  1/14 (7)  0.47  1/14 (7)  0.47  2/14 (14)  0.21
BPA-1000 (n = 13)  1/13 (8)  0.45  1/13 (8)  0.45  2/13 (15)  0.19
Incidence does not include ovarian cysts or CEH. 
aRelative to controls by Fisher’s exact test. bIncludes one animal with uterine hemangioma. cIncludes one animal with 
poorly differentiated sarcoma in the ovary and reproductive tract (probably hematopoetic in origin). Newbold et al.
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In summary, the findings of the present 
study raise concerns about widespread exposure 
to BPA and, in particular, exposure to fetuses, 
infants, and children. In vitro studies showing 
that BPA transforms SHE cells (Tsutsui et al. 
2000) and induces aneuploidy (Tsutsui et al. 
1998), and previous in vivo studies showing 
that BPA causes mammary tumors (Durando 
et al. 2007; Murray 2007) and preneoplas-
tic prostatic lesions (Ho et al. 2006), along 
with evidence of BPA carcinogenicity follow-
ing adult exposure (Huff 2001) together indi-
cate that the body of literature merits serious 
consideration. Although studies are needed 
to determine the potential adverse effects to 
humans exposed to BPA during criti  cal stages 
of neo  natal or early development, the potential 
risks and benefits should be thoroughly assessed 
to determine the appropriate balance of expo-
sures of this chemical during development and 
the permanent effects that may follow. 
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